Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-01-28

Clinical Trial Update: Protein Kinase C (PKC) Inhibitor-Diabetic Retinopathy Phase 3 Study [Phase 3]

View source ↗

Summary

Phase 3 trial update reporting completed study and posted results for a protein kinase C inhibitor in diabetic retinopathy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Ruboxistaurin (ruboxistaurin)

Snippet

Sponsor: Chromaderm, Inc. | Conditions: Diabetic Retinopathy | Phase 3 | Status: COMPLETED | Results posted: 2016-01-28